⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 21, 2024Clinical Nuclear Medicine

225Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy

Florian Rosar Caroline Burgard Luna Vanessa Rohloff Arne Blickle Mark Bartholomä Stephan Maus Sven Petto Andrea Schaefer-Schuler Samer Ezziddin

View Full Paper

Ask AI

Bookmark

Share

Abstract

This pilot study investigates the efficacy and safety profile as well as predictive biomarkers of 225 Ac-PSMA-617-augmented 177 Lu-PSMA-617 radioligand therapy (RLT) in a cohort of high-risk patients with metastatic castration-resistant prostate cancer (mCRPC), enrolled in a prospective registry (NCT04833517).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rosar et al. (2024) studied this question.

synapsesocial.com/papers/68e69105b6db643587617f0f https://doi.org/10.1097/rlu.0000000000005253

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1PSMA-Radioligandentherapie – State of the Art2025
2Personalized dosimetry assessment of [ <sup>177</sup> Lu]Lu-PSMA-617 radioligand therapy in the management of metastatic castration-resistant prostate cancer2024 · 8 citations
3Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer2025
4Therapeutic outcomes of ²²⁵Ac/¹⁷⁷Lu-PSMA combination therapy in advanced metastatic Castration-Resistant prostate cancer: A systematic review and Meta-Analysis2025
5Actinium-225-PSMA versus lutetium-177-PSMA radioligand therapy for metastatic castration-resistant prostate cancer: results of an observational studyObservational Study · 2026